Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1SATRALIZUMAB
(D11079)		[1] Satralizumab[1] Satralizumab (D11079) 💬[1] IL6R 💬[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[3] 11, 13, 86 💬
2Satralizumab (120 mg/PFS with NSD)
(D11079)		[1] Satralizumab[1] Satralizumab (D11079) 💬[1] IL6R 💬[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 13 💬
3Satralizumab (120 mg/vial)
(D11079)		[1] Satralizumab[1] Satralizumab (D11079) 💬[1] IL6R 💬[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 13 💬
4Satralizumab (120mg/vial)
(D11079)		[1] Satralizumab[1] Satralizumab (D11079) 💬[1] IL6R 💬[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 13 💬
5Satralizumab (Genetical Recombination)
(D11079)		[1] Satralizumab[1] Satralizumab (D11079) 💬[1] IL6R 💬[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 86 💬
6Satralizumab (r-INN)
(D11079)		[1] Satralizumab[1] Satralizumab (D11079) 💬[1] IL6R 💬[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 13 💬
7Satralizumab (RO5333787/Enspryng /SA237)
(D11079)		[1] Satralizumab[1] Satralizumab (D11079) 💬[1] IL6R 💬[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 13 💬
8Satralizumab (RO5333787/Enspryng/SA237)
(D11079)		[1] Satralizumab[1] Satralizumab (D11079) 💬[1] IL6R 💬[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 13 💬
9Satralizumab (RO5333787/SA237)
(D11079)		[1] Satralizumab[1] Satralizumab (D11079) 💬[1] IL6R 💬[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 13 💬
10Satralizumab 120 mg
(D11079)		[1] Satralizumab[1] Satralizumab (D11079) 💬[1] IL6R 💬[12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 13 💬